Investment
Features
FeesSafety
Academy
More
Pluang+

UNFI Q4 revenue dips 1.6% but EPS rebounds to $0.61-$0.62, signaling strong profit recovery

Company Fundamentals
04 Sep 2026
Alex Lavoie
View Source
Bullish
UNFI Q4 revenue dips 1.6% but EPS rebounds to $0.61-$0.62, signaling strong profit recovery

United Natural Foods (UNFI) is set to report Q4 earnings with revenue expected around $7.71 billion, a slight 1.6% decline from last year due to network optimization. Despite the revenue drop, EPS is forecasted to rise sharply to $0.61-$0.62, a significant improvement from a $0.11 loss per share a year ago, driven by productivity gains. The company maintains a solid liquidity position with a current ratio of 1.33, though it carries a debt-to-equity ratio of 1.97. This earnings report, due September 8, 2026, will be closely watched as it reflects UNFI's operational improvements and financial health.

More News

Oracle's strong financials and AI investments boost analyst price target by 36%.

Oracle's strong financials and AI investments boost analyst price target by 36%.

Oracle reported strong fiscal 2026 results with 17% revenue growth to $67 billion and a 36% net income increase, driven by a 75% surge in its cloud infrastructure segment. Despite a recent 55% stock price drop from its peak, Morgan Stanley raised Ora...

Analyst Insights
Bullish
1 hour ago
RBC Capital raises Zscaler price target to $210 on strong revenue growth and AI-driven innovation.

RBC Capital raises Zscaler price target to $210 on strong revenue growth and AI-driven innovation.

RBC Capital increased its price target for cybersecurity firm Zscaler to $210, maintaining an "Outperform" rating due to the company's strong financial results and AI innovation. Zscaler reported a 25% rise in revenue and Annual Recurring Revenue, su...

Analyst Insights
Bullish
1 hour ago
Lululemon shares drop 18% as company cuts full-year forecast amid sales decline.

Lululemon shares drop 18% as company cuts full-year forecast amid sales decline.

Lululemon Athletica's shares fell about 18% after the company lowered its full-year financial forecast for the second time, reflecting ongoing challenges. In Q2 2026, total net revenue dropped 4% to $2.40 billion, with a 10% fall in comparable sales ...

Company Fundamentals
Bearish
2 hours ago
Teva gains bullish momentum after positive celiac disease trial and UBS upgrades price target to $48

Teva gains bullish momentum after positive celiac disease trial and UBS upgrades price target to $48

Teva Pharmaceutical Industries received a boost as UBS reaffirmed its "Buy" rating and raised the price target to $48, up from $36.62. This follows positive Phase 2a clinical trial results for TEV '408, a drug showing significant prevention of intest...

Analyst Insights
Bullish
2 hours ago
UiPath posts strong Q2 but faces cautious outlook due to AI competition and insider selling

UiPath posts strong Q2 but faces cautious outlook due to AI competition and insider selling

UiPath reported strong fiscal Q2 results with $410.26 million revenue and 12% ARR growth, beating estimates. However, analyst caution arises from its high valuation, modest growth compared to AI-focused peers, and recent insider selling by CEO and ex...

Company Fundamentals
Neutral
3 hours ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App